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Two antibodies, BT14 and L101, detect a tumor-associated cell surface glycoprotein (gp130) whose properties in
normal and diseased skin were assessed, and whose molecular identity was determined in this study. In normal
skin, gp130 was constitutively expressed on dermal blood vessels and epidermal appendages, but not in
interfollicular epidermis. Marked induction was detected within benign and malignant tumors of various origins
including viral warts, basal cell carcinomas, squamous cell carcinomas, metastatic melanomas, and cutaneous T
cell lymphomas. In vitro studies conﬁrmed the general upregulation of gp130 expression in malignantly trans-
formed cells. Surprisingly, gp130 was also induced in inﬂammatory skin diseases including psoriasis and allergic
contact dermatitis. Halting proliferation of transformed keratinocytes through cytostatic drugs or increasing the
Ca2þ concentration in the medium resulted in increased gp130 expression. In addition, overexpression of Bcl-2 led
to upregulation of gp130. When the protein was puriﬁed and analyzed by peptide mass ﬁngerprinting, we could
demonstrate that it is MUC18 (Mel-CAM, CD146). Sequential immunoprecipitations and western blot analyses
conﬁrmed the identity of the antigen. Thus, both expression pattern and regulation characteristics of the now-
known glycoprotein gp130 extended beyond previously published data regarding MUC18, thus shedding some new
light on a supposedly well-known antigen.
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Monoclonal antibodies (mAb) targeting tumor-associated
antigens have been developed as diagnostic or therapeutic
tools against a variety of malignancies (Houghton et al,
1982; Real et al, 1985; Guevara-Patino et al, 2003; Kuroki
et al, 2003; Schmidt and Wood, 2003; Zhang, 2004). On the
one hand, the detection of antigens whose expression pat-
terns differ between normal cells and their malignant coun-
terparts has furthered our understanding of tumor biology
and potential therapeutic approaches. On the other, how-
ever, the study of so-called tumor-associated antigens has
also shed light on important functions of normal cells, as
many of these antigens may be expressed during certain
functional or developmental stages of normal cells and me-
diate such important functions as cell adhesion, motility, or
response to growth factors and other mediators (Suminami
et al, 1998; Scho¨n et al, 2000; O¨hman Forslund and Nor-
dqvist, 2001). Tumor antigen-directed antibodies can either
be used as unlabeled molecules to induce antibody-de-
pendent cytotoxicity or complement mediated lysis, or they
can be used in conjugation with other moieties such as
toxins or radioactive nucleids (Kuroki et al, 2002). Prominent
examples demonstrating the applicability of such strategies
in principle are the clinical use of chimeric antibodies di-
rected against the Her2/neu receptor in breast cancer (Ross
and Gray, 2003; Ross et al, 2004), the epidermal growth
factor receptor in colon and head/neck cancer (Salgaller,
2003; Rogers et al, 2004), or the vascular endothelial growth
factor in lung and colon cancer (Willett et al, 2004). With the
discovery of newer targets and means to manipulate mol-
ecules to generate tailor-made antibody fragments, the field
of antibody-based targeted cancer therapy appears to be
promising (Kuroki et al, 2002; Schmidt and Wood, 2003).
But despite the fact that some antibody-defined mole-
cules have been found to be dysregulated in certain ma-
lignant tumors and have been studied for a long time, the
exact functions and/or molecular nature of several of these
antigens still remains to be elucidated.
Among the rather poorly characterized tumor-associated
antigens is a cell surface glycoprotein of 130 kDa that is
recognized by the two murine monoclonal antibodies, L101
and BT14. Gp130 was first described as a tumor-associ-
ated antigen in an analysis of eight mAb produced against
human melanomas (Dippold et al, 1980). It was found later
that gp130 was upregulated in human melanoma and as-
trocytoma cells, but is also expressed, albeit to a lesser
extent, by several other malignant and normal cell types
(Dippold et al, 1980; Albino et al, 1983; Real et al, 1985). In
addition, it has been shown previously in an elegant study
that gp130 is growth-controlled in some cultured human
Abbreviations: FCS, fetal calf serum; mAb, monoclonal antibody;
MALDI-TOF, matrix-assisted laser desorption/ionization-time of
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cells (Klein et al, 1988). Beyond these biochemical and reg-
ulation studies, however, little information was available on
this antigen. In particular, its molecular identity has not yet
been determined.
Given that gp130 expression in human skin disorders,
with the exception of melanoma, was largely unknown, we
were first interested in its expression profile in normal skin
as well as a variety of inflammatory and malignant skin
disorders. Thereafter, we have extended the biochemical
analysis and have performed experiments regarding its
regulation in vitro. Since the expression pattern and our
in vitro data regarding gp130 did not exactly match known
surface glycoproteins, we have analyzed the molecule to
determine its identity. Surprisingly, we could demonstrate
(and confirm this by sequential immunoprecipitation and
western blot analyses) that gp130 is identical to MUC18
(Mel-CAM, CD146), thereby shedding some unexpected
new light on a supposedly well-known molecule.
Results
Gp130 is expressed in skin tumors of various origins,
but not in normal epidermis When expression of gp130
in normal human trunk skin (n¼ 5) was assessed by
immunohistochemistry using the BT14 or L101 mAb, it
was found that expression of this antigen was restricted to
endothelial cells of dermal blood vessels, throughout the
outer root sheath of anagen hair follicles, sebaceous glands,
and eccrine sweat glands (Table I). Interfollicular epidermis
of normal skin (comprising keratinocytes, melanocytes, Me-
rkel cells, and Langerhans cells) did not show reactivity (Fig
1a). In contrast, common viral warts (i.e., benign hyperpro-
liferative epidermal tumors; n¼ 3), showed moderate de
novo expression of gp130 within suprabasal layers of the
hyperplastic epidermis (Table I). When invasive malignant
epithelial tumors were analyzed, we found focal moderate
to strong expression of gp130 within tumor nests of 8/11
(i.e., 72%) of basal cell carcinomas (BCC; Fig 1b) as well as
in six of six squamous cell carcinomas (SCC; Fig 1c and
Table I). In undifferentiated SCC, we detected tumor cells
expressing gp130 dispersed throughout the tumor tissue,
whereas in differentiated SCC, staining was observed pref-
erentially in the suprabasal areas (Fig 1c). To confirm the de
novo expression of gp130 in epithelial tumors by a second
method, we isolated normal epidermis as well as SCC tis-
sue from the underlying connective tissue by tryptic diges-
tion, lyzed the isolated normal keratinocytes and SCC cells,
respectively, and subjected the lysates to western blot
analysis. As expected, we detected a strong signal at a
molecular weight of approximately 130 kDa in the SCC
lysates, but not in lysates of keratinocytes purified from
normal epidermis (Fig 1d).
To assess whether gp130 was also expressed by cuta-
neous tumors of other origins, we studied melanomas and
cutaneous T cell lymphomas (CTCL). As expected (Dippold
et al, 1980), moderate to very strong expression of gp130
was detected in eight of eight metastases of melanoma (Fig
1e and Table I). In addition, gp130 was expressed in four of
four cases of CTCL. In three of three CTCL of the plaque
type, gp130 was expressed by some skin-infiltrating mono-
nuclear cells (Fig 1f, left panel), whereas in one case of tumor-
stage CTCL, most infiltrating cells showed strong reactivity
(Fig 1f, right panel). A dermatofibrosarcoma protuberans
showed no reactivity with mAb directed against gp130.
Interestingly, in most malignant tumors (BCC, SCC, me-
lanoma, CTCL) investigated in our study, there was prom-
inent patchy or confluent induction of gp130 in suprabasal
layers of normal-appearing epidermis overlying the invasive
tumors (examples depicted in Fig 1b, e, and f), whereas the
epidermis of healthy skin showed no expression. This find-
ing suggested that expression of gp130 can be induced by
microenvironmental factors other than malignant transfor-
mation, similar to what has been found with other tumor-
associated antigens (Scho¨n et al, 2000).
Increased expression of gp130 in tumor cells of various
origin in vitro In order to analyze the expression and reg-
ulation of gp130 in more detail in vitro, we performed west-
ern blot (Fig 2) and flow cytometry (not shown) analyses
using a panel of 14 different normal and transformed human
cell lines. In support of our immunohistochemical findings,
freshly isolated normal human keratinocytes or keratin-
ocytes of primary cultures did not express gp130 in vitro
(Fig 2a, third lane). When keratinocytes of higher passages
were assessed, however, we detected weak expression
of gp130 in some experiments, indicating induction of
the antigen under culture conditions (data not shown).
In contrast, normal human dermal microvascular endothelial
cells showed very strong constitutive expression of gp130
(Fig 2a, ﬁrst lane). PHA-stimulated human peripheral
blood mononuclear cells (lymphoblasts) showed weak
constitutive reactivity with the BT14 or L101 mAb (Fig 2a,
second lane). The peripheral blood lymphocytes expression
of gp130 increased with the concentration of PHA; consist-
ent with previous reports (Pickl et al, 1997), stepwise ele-
vation of the PHA concentration from 1 to 5 mg per mL
resulted in a 3-fold increase of gp130 expression as de-
tected by fluorescence-activated cell scanning (FACS) anal-
yses (not shown).
All of the transformed or immortalized cell lines studied
showed clear expression of gp130 (Fig 2a, the ﬁve right
lanes). When transformed cells of keratinocytic origin, i.e.,
spontaneously immortalized aneuploid keratinocytes (Ha-
CaT cells), a squamous cell carcinoma cell line (SCL-1), and
two virally transformed keratinocyte lines (cell lines 425 and
130), were studied, marked expression of gp130 was noted
in all of these lines (Fig 2a depicts the cell lines 425 and
SCL-1). Other epithelial tumor lines, i.e., the mammary car-
cinoma cell line HTB-26 and the colon carcinoma cell line
SK-CO-2, also showed expression of gp130 (Fig 2a, lanes 7
and 8). The strongest expression, however, was observed in
a panel of five different melanoma cell lines (SK-Mel-23,
A375, Mel-HO, Mel-2a, MeWo; Fig 2b).
Gp130 is sialylated and N-glycosylated In order to further
analyze the biochemical characteristics of gp130, we as-
sessed its glycosylation using human dermal microvascular
endothelial cells (i.e., a normal cell line that constitutively
expresses gp130, Fig 3a, upper panel), the melanoma cell
line SK-Mel-23 (Fig 3a, middle panel), and the virally trans-
formed keratinocyte cell line 425 (Fig 3a, bottom panel)
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as sources of gp130. Following immunoprecipitation, the
BT14/gp130 immune complexes were treated with neur-
aminidase to hydrolyze terminal N- or O-acylneuraminic
acids. This treatment resulted in reduction of the molecular
weight of gp130 to approximately 120 kDa (Fig 3a, lane 2).
Subsequent digestion with O-Glycanase in order to remove
O-linked glycans did not result in detectable further reduc-
tion of the molecular weight (Fig 3a, lane 3). But, treatment
of the gp130 immune complexes with N-glycosidase F, an
enzyme that cleaves all types of asparagine bound N-linked
glycans, resulted in further reduction of the molecular
weight to about 116 kDa. The pattern of deglycosylation
achieved with the three enzymes was similar in all the three
cell lines studied. The higher molecular weight of gp130 in
SK-CO-2 cells may result from differential glycosylation (as
has been described for other surface glycoproteins in some
tumor cells (Scho¨n and Orfanos, 1995)). When the L101
mAb was used to detect the gp130 deglycosylation prod-
ucts, the same pattern as detected with the BT14 mAb was
seen (not shown).
Expression of gp130 is regulated in association with
distinct functional states of keratinocytes Based on our
immunohistochemical and in vitro expression studies, it ap-
peared that normal interfollicular keratinocytes do not express
gp130, but can be stimulated to express the antigen following
transformation. In addition, there was expression of gp130 in
cultured keratinocytes of higher passages and in suprabasal
layers of normal-appearing epidermis in the vicinity of inva-
sive tumors, suggesting that transformation-independent
mechanisms exist that regulate gp130 expression. Given
that, in the latter case, expression was only found in supra-
basal layers of the epidermis, gp130 expression appeared to
be associated with terminal differentiation of human keratin-
ocytes under certain conditions. Therefore, we investigated
the influence of factors known to regulate keratinocyte dif-
ferentiation and apoptosis on expression of gp130.
In the first series of experiments, we incubated grow-
ing cultures of keratinocytes in medium containing a very
low concentration of serum (0.5% fetal calf serum
(FCS)). After 4 d, the serum starvation was either continued,
cultures were stimulated for 3 d with 20% FCS, or were
treated for the last 24 h with the cytostatic drugs hydro-
xyurea and mitomycin C, respectively (Fig 3b). When
the synthesis of gp130 and two unrelated control mem-
brane glycoproteins, basal-cell adhesion molecule B-CAM)
Table I. Synopsis of the expression pattern of gp130 in normal tissues and various malignant and inﬂammatory skin disorders as




Placenta 2 Blood vessels þ þ þ
Normal skin 5 Blood vessels þ þ þ , sweat glands, and sebaceous
glands þ þ , epidermis , outer root sheath of hair follicles þ to þþ
Basal cell carcinoma 11 Focal expression within tumor nests (þ to þ þ ) in eight
of 11 tumors; suprabasal expression in normal-appearing
epidermis overlying the tumor (þ to þ þ )
Squamous cell carcinoma 6 Focal expression (predominantly suprabasal, þ to þ þ ) in
six of six tumors; suprabasal expression in normal-appearing
epidermis overlying the tumor (þ to þ þ )
Common warts 3 Suprabasal expression (þ )
Metastatic melanoma 8 Focal expression within the tumor tissue (þ to þ þ þ ) in eight
of eight tumors; suprabasal expression in normal-appearing




4 Focal suprabasal expression in the epidermis (þ ) in four of four
specimens; expression on some skin-infiltrating mononuclear cells
(þ ) in three of three specimens of plaque-type mycosis fungoides;
expression on most infiltrating cells (þ to þ þ ) in one case of
tumor-stage mycosis fungoides (þ þ )
Dermatofibrosarcoma
protuberans
1 No expression () in tumor tissue
Psoriasis 10 Blood vessels þ þ þ , focal suprabasal expression (þ to þ þ )
in eight of ten tissue specimens
Dermatitis 6 Blood vessels þ þ þ ; focal to confluent suprabasal expression (þ þ )
in three of three tissue specimens of acute dermatitis; focal weak
expression in three of three specimens of chronic dermatitis (þ / to þ )
Prurigo simplex 2 Blood vessels þ þ þ ; focal epidermal expression (þ to þ þ ) in one of
two cases
Sweet’s syndrome 1 Blood vessels þ þ þ ; suprabasal epidermis þ þ
mAb, monoclonal antibodies; , no expression;þ /, weak expression; þ , moderate expression; þ þ , strong expression; þ þ þ , very strong
expression.
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(Scho¨n et al, 2000), and gp80 (Scho¨n et al, 1995), was
assessed by radioimmunoprecipitation in the cultures
after metabolic labeling with 35S-methionine, it was found
that gp130 did not change significantly under the influence
of different serum concentrations (Fig 3b). Synthesis of
gp130, however, was moderately upregulated following
treatment with hydroxyurea, and strong upregulation
of gp130 was seen in cultures treated with mitomycin C
(Fig 3b).
Given that some cytostatic drugs including mitomycin C
exert their effect, at least in part, through induction of
apoptosis, and intrigued by the suprabasal expression of
gp130 under certain conditions (i.e., in epidermal layers
committed to terminal differentiation), we tested the hy-
pothesis that expression of gp130 was associated with
apoptosis in cultured cells. Towards this end, we utilized
HaCaT cells and two melanoma cell lines stably overex-
pressing murine Bcl-2, an anti-apoptotic protein that
confers resistance to various pro-apoptotic stimuli (Mu¨ller-
Wieprecht et al, 2000; Scho¨n et al, 2003, 2004). As com-
pared with their mock-transfected counterparts, Bcl-2-
overexpressing cells showed a moderate but consistent
increase of gp130 expression (Fig 3c). In contrast, expres-
sion of gp80 was lower in the Bcl-2 overexpressing HaCaT
cells as compared with the mock transfectants (not shown).
In complementary experiments, we tested the hypothesis
that gp130 expression was associated with terminal differ-
entiation of human keratinocytes. Towards this end, normal
keratinocytes as well as the SV40-transformed keratinocyte
line 130 were cultured in medium containing low (i.e.,
o0.1 mM) or high concentrations (i.e., 1.0 mM) of Ca2þ for
3 d. Culturing keratinocytes in the presence of high Ca2þ
Figure 1
Gp130 is upregulated in skin tumors.
Frozen sections of normal trunk skin (a,
representative of five specimens), two ba-
sal cell carcinomas (BCC) (b, the left pho-
tomicrograph depicts an incipient tumor
and the right panel depicts a nodular
BCC, representative of 11 BCC speci-
mens), and two squamous cell carcino-
mas (SCC) (c, the left panel depicts a
differentiated SCC and the right panel de-
picts an undifferentiated SCC; represent-
ative of six SCC specimens) were stained
with the gp130-specific monoclonal anti-
body (mAb) BT14 as described in Mate-
rials and Methods. The arrow indicates
examples of dermal blood vessels. Scale
bars¼50 mm. d shows a western blot
analysis (using the BT14 mAb in the top
panel, and an antibody directed against b-
actin in the bottom panel) of lysates pre-
pared from normal epidermis (left lane)
and isolated tumor tissue of a SCC (right
lane), confirming the de novo expression
of gp130 in epithelial skin tumors. In e, a
cutaneous metastasis of a melanoma
(representative of eight specimens; ar-
rows identify blood vessels, the circle in-
dicates tumor tissue, and the asterisk
marks epidermal staining), and in f, two
cases of cutaneous T cell lymphoma (the
left panel depicts a plaque stage and
the right panel depicts a tumor stage; the
circles identify infiltrating mononuclear
cells and the asterisks indicate epider-
mal expression) were stained for gp130
expression using the BT14 mAb. Scale
bars¼50 mm.
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concentrations is known to induce terminal differentiation.
Indeed, FACS analyses showed a moderate but consistent
increase of gp130 cell surface expression by approximately
28% following induction of terminal differentiation (Fig 3d).
Likewise, gp130 expression was elevated by 35% in the
virally transformed keratinocyte line 130 grown under high-
calcium conditions (Fig 3d, bottom panel). Growing the ker-
atinocytes (cell line 130) in medium containing phorbol 12-
myristate 13-acetate (PMA), which is known to act as an
activator of protein kinase C, a decrease in cell surface ex-
pression of gp130 by 20%–30% was observed (Fig 3d).
In another series of experiments, we cultured human
keratinocytes in the presence of various candidate cyto-
kines, including IL-1a (20 pg per mL), TNF-a (5 ng per mL),
GM-CSF (2 ng per mL), IFN-g (100 ng per mL), VEGF (20 ng
per mL), or IL-8 (25 ng per mL). In addition, cocktails of IL-
1a, TNF-a, and GM-CSF, or IFN-g and IL-8 were used.
When gp130 expression was analyzed by FACS, however,
clear and consistent modulation of gp130 surface expres-
sion could not be detected, although there appeared to be
some inconsistent upregulation of gp130 by VEGF in some
experiments (data not shown).
Consistent with previous studies using a human antibody
(Mills et al, 2002; McGary et al, 2003), incubation of two
melanoma cell lines (A375 and Mel-2a) with the BT14 or
L101 mAb, respectively, failed to result in significant chang-
es of cell proliferation, although there was a tendency to-
ward lower proliferation in the presence of either of the two
mAb as compared with control conditions (data not shown).
Gp130 is expressed in benign inﬂammatory skin disor-
ders Intrigued by the expression of gp130 in normal-ap-
pearing epidermis in the vicinity of invasive tumors, we
performed more immunohistochemical stainings to analyze
its expression in a number of benign inflammatory skin dis-
orders (Fig 4). Indeed, we detected prominent reactivity
within suprabasal layers of the epidermis in chronic and
acute dermatitis (six of six cases), prurigo simplex (one of
two cases), psoriasis vulgaris (eight of ten cases, both
within the suprapapillary epidermis and the elongated rete
ridges), and one case of Sweet’s syndrome (Fig 4a–d). In
contrast, B-CAM, another tumor-associated membrane
glycoprotein that is expressed constitutively on blood ves-
sels and may be induced in the epidermis in some inflam-
matory disorders (Scho¨n et al, 2000), was induced in the
basal keratinocyte layers, thus showing an antipodal ex-
pression pattern as compared with gp130 in the epidermis
(Fig 4d depicts two sequential sections stained for gp130
and B-CAM reactivity).
Molecular identiﬁcation of gp130 as CD146 (MUC18) An
extensive literature search was performed in order to iden-
tify a known cell-surface glycoprotein whose expression
and regulation characteristics matched those determined
for gp130. Our observations, however, did not match any of
the known cell surface glycoproteins. This prompted us to
purify gp130 and to determine its amino acid sequence in
order to unravel its molecular nature. As a rich source of the
protein, we used human placenta, after we had established
that gp130 was highly expressed in this tissue (Table I).
Cultured cells did not yield the amounts of protein needed
for successful analysis, although we have later confirmed
the results obtained with placenta-derived gp130 with pro-
tein purified from a cultured melanoma line. The protein was
purified by immune affinity chromatography and, subse-
quently, subjected to tryptic digestion, and analyzed and
identified by Peptide-mass-fingerprinting on a matrix-as-
sisted laser desorption/ionization-time of flight-mass spec-
troscopy (MALDI-TOF-MS) as described in Material and
Methods. Surprisingly, the Mascot Search Result identified
gp130 clearly to be MUC18 (CD146, Mel-CAM) with a
probability-based mowse score of 142 (protein scores
greater than 59 are significant, po0.05).
To confirm this unexpected finding, serial cryostat-
cut sections of normal skin and SCC were used for
immunohistochemistry using the BT14 mAb as well as the
commercially available P1H12 mAb that is directed
against CD146 (MUC18). Indeed, both mAb, BT14 and
P1H12, showed similar patterns of reactivity (Fig 5a). It ap-
peared, however, that the BT14 mAb yielded a more intense
staining and that not all of the dermal blood vessels rec-
ognized by the BT14 mAb were reactive with the P1H12
mAb (Fig 5a).
To formally prove the identity of the antigens recognized
by the BT14 or L101 mAb and the commercially available
Figure 2
Expression of gp130 in normal and transformed cell lines in vitro. In
a, lysates (10 mg of total protein per lane) of human dermal microvascular
endothelial cells (lane 1), peripheral blood mononuclear cells (lane 2),
normal human keratinocytes (primary culture, lane 3), the SV40-trans-
formed keratinocyte line 425 (lane 4), the squamous cell carcinoma cell
line SCL-1 (lane 5), the melanoma cell line SK-Mel-23 (lane 6), the colon
carcinoma cell line SK-CO-2 (lane 7), and the mammary gland carcinoma
line HTB-26 (lane 8) were separated by sodium dodecyl sulfate polya-
crylamide gel electrophoresis, immunoblotted, and stained with mon-
oclonal antibodies BT14 (upper panel) or L101 (bottom panel) as outlined
in Material and Methods. Signals were visualized by the enhanced
chemiluminescence method. In b, expression of gp130 in the indicated
five different melanoma cell lines was analyzed as outlined above.
gp130 IDENTIFIED AS CD146 357125 : 2 AUGUST 2005
CD146-specific mAb on the protein level, we performed
sequential immunoprecipitation/western blot experiments
using all three mAb, BT14, L101, and P1H12, in all possible
combinations. In these experiments, the immune complex-
es generated by immunoprecipitation with the respective
first mAb were resolved on a sodium dodecyl sulfate (SDS)
gel. In the second step, the precipitated proteins were de-
tected by western blot analysis using the respective other
antibody (Fig 5b). With all of the combinations of mAb, the
gp130 glycoprotein immunoprecipitated in the first step was
recognized in western blot analysis by the respective other
mAb (Fig 5b). The commercially available antibody P1H12,
however, worked rather weakly in western blotting, but
worked well in immunoprecipitation. Thus, our experiments
provided formal proof that gp130 is identical to CD146
(MUC18, Mel-CAM).
Figure 3
Glycosylation and regulation of gp130 in vitro. In a, gp130 was immunoprecipitated from lysates of human dermal microvascular endothelial cells
(top panel), the melanoma cell line SK-Mel-23 (middle panel), and the SV40-transformed keratinocyte line 425 (bottom panel). The immune
complexes were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis either undigested (lane 1), after treatment with ne-
uraminidase (lane 2), after treatment with neuraminidase and O-glycanase (lane 3), or after treatment with N-glycosidase (lane 4), and immunoblotted
to visualize gp130. In b, the virally transformed human keratinocyte line 425 was cultured in medium containing low (0.5%, top panel, three left lanes)
or high (20%, top panel, three right lanes) concentrations of fetal calf serum (FCS). Parallel cultures (bottom panel) were treated with hydroxyurea or
mitomycin C as outlined in the text. The cultures were metabolically labeled with 35S-methionine, and gp130 was immunoprecipitated from the cell
lysates using the BT14 monoclonal antibody (mAb) (right lanes as indicated in each panel). Two unrelated cell-surface glycoproteins, gp80, and
basal-cell adhesion molecule, recognized by the BT15 and VF18 mAb, respectively, were also precipitated from the same lysates for comparison. c
depicts expression of gp130 in HaCaT cells and two melanoma cell lines (Mel-HO and A375) that were either mock transfected (lanes 1, 3, and 5) or
transfected with the murine bcl-2 to confer resistance against apoptosis (lanes 2, 4, and 6). Gp130 was detected in lysates of the cell lines by
western blot analysis using the BT14 mAb. d demonstrates cell surface expression of gp130 as detected by FACS analysis in normal keratinocytes
(three upper histograms) and the SV40-transformed keratinocyte line 130 (three lower histograms) cultured in the presence of low Ca2þ con-
centrations (left), high Ca2þ concentrations (middle), or TPA (right) as outlined in the text. MFI, mean fluorescence intensity.
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Discussion
This study was initiated in order to further characterize the
tumor-associated membrane glycoprotein, gp130. In the
course of the project, however, by elucidating some novel
aspects of the expression and regulation pattern of this an-
tigen on the one hand, and by demonstrating its molecular
identity as being MUC18 (CD146) on the other, we have
merged two lines of previous investigations, thus shedding
new light on a supposedly well-known molecule.
MUC18 (CD146, also termed Mel-CAM, A32 antigen, or
S-Endo-1) was described in previous studies as a marker
for tumor progression and metastasis in human melanomas
(Lehmann et al, 1987, 1989; Shih et al, 1994a, b). It has been
shown later that the molecule has a broader tissue distri-
bution, as it was also detected on endothelial cells, smooth
muscle cells, in the cerebellar cortex, in the intermediate
trophoblast, on some activated T cells, and in breast epi-
thelium (Bardin et al, 1996a, b; Hampel et al, 1997; Pickl
et al, 1997; Schwarz et al, 1998). CD146 is a member of the
immunoglobulin superfamily of adhesion molecules as in-
dicated by its characteristic extracellular structure com-
posed of five Ig-like domains (V–V–C2–C2–C2) (Lehmann
et al, 1989; Sers et al, 1993). It has been proposed that
MUC18 functions as a heterophilic cell–cell adhesion mol-
ecule that binds to an as yet unidentified ligand on the sur-
face of adjacent cells (Johnson et al, 1996; Shih et al, 1997).
Most studies concerning expression and function of CD146
have been performed on melanoma cells (Johnson et al,
1997; Xie et al, 1997a, b). In a more recent report, ex-
pression of CD146 was also described on keratinocytes
(Weninger et al, 2000). In that study, however, constitutive
expression in cultured normal keratinocytes, but not in
transformed keratinocytes was reported. With our antibod-
ies, we found strong reactivity in most of the basal cell car-
cinomas and in all of the squamous cell carcinomas and
melanomas analyzed. In addition, expression in cutaneous
T cell lymphomas was observed. These results were in
contrast to an immunohistochemical study using the
CD146-directed antibody, MN-4, in which staining of cuta-
neous melanomas was described but all of the BCC, SCC,
and T cell lymphomas were negative for CD146 reactivity
(Shih et al, 1998). Overall, the as yet published expression
pattern of CD146 in tumors suggested preferential expres-
sion in melanomas, whereas epithelial tumors had been re-
ported to be largely negative in some studies (Shih, 1999),
whereas other authors reported some reactivity when a dif-
ferent antibody was used (Weninger et al, 2000). In any
case, based on the results of our study, CD146 appears to
have a wider tissue distribution in the skin than was dis-
cernible from previous studies. It appears that the expres-
sion and regulation pattern of CD146 in invasive tumors of
different cellular origin and in other pathological conditions
is not straightforward and that it is possible that the anti-
genic epitope recognized by the monoclonal antibodies
reported thus far may be expressed differentially under
certain conditions. In addition, the heterogenous expres-
sion of CD146 in functionally distinct tissues makes
reasonable expression-based assumptions regarding its
biological role difficult. We have, however, performed
a number of experiments to assess factors regulating
gp130 expression, which then turned out to describe
features of CD146.
We have demonstrated constitutive expression of gp130
on the surface of all of the transformed keratinocyte cell
lines studied in vitro. In addition, suprabasal expression by
keratinocytes was detected under various pathological con-
ditions in vivo, suggesting an association with a certain
state of ‘‘activation’’ of keratinocytes committed to terminal
differentiation. It remains somewhat enigmatic, however,
how CD146 expression is regulated in vivo. Pro-inflamma-
tory cytokines, which are expressed both in inflammatory
skin conditions and in some tumors, are obvious candidate
mediators; yet, our experiments as well as two previous
studies (Rummel et al, 1996; Weninger et al, 2000) failed to
demonstrate such activity of a panel of cytokines. This does
not, however, formally rule out the possibility that the
cytokines tested in the three studies contribute to CD146
induction in the in vivo situation, possibly together with
other, not yet tested mediators.
The hypothesis that CD146 expression is regulated along
with the state of differentiation of human keratinocytes was
supported by our observation that surface expression of
Figure 4
Gp130 is expressed in the epidermis of benign inflammatory skin
disorders. Cryostat-cut sections from allergic contact dermatitis (a,
acute (top) and chronic (bottom) state), prurigo simplex (b), psoriasis
vulgaris (c) and Sweet’s syndrome (acute febrile neutrophilic de-
rmatosis, d) were stained using the gp130-directed BT14 monoclonal
antibody (mAb). In the two right-hand photomicrographs of d, two serial
sections of a skin lesion of Sweet’s syndrome were stained with the
BT14 mAb and the VF18 mAb; the latter mAb is directed against basal-
cell adhesion molecule to demonstrate antipodal expression of the two
antigens in inflamed human epidermis. Scale bars¼50 mm.
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gp130 could be increased both on normal and on trans-
formed keratinocytes by elevating the Ca2þ concentration
in the medium, a condition known to induce terminal dif-
ferentiation in keratinocytes. These results are consistent
with the in vivo observation that gp130 is expressed by cells
in the suprabasal, non-proliferating layers of the epidermis
under certain conditions.
The hypothesis of an association with growth arrest and/
or terminal differentiation of keratinocytes under certain
(e.g., inflammatory) conditions was further supported by our
observation that the cytostatic compounds mitomycin C
and, albeit to a lesser extent, hydroxyurea, induced upreg-
ulation of CD146 in vitro. These compounds exert their
cytostatic effect, at least to a considerable extent, through
induction of apoptosis. Indeed, an association of CD146
expression with susceptibility of cells to undergo apoptosis
was supported by our study inasmuch as we could dem-
onstrate that cells that are resistant against various pro-
apoptotic stimuli through overexpression of Bcl-2 (Mu¨ller-
Wieprecht et al, 2000; Scho¨n et al, 2003, 2004) expressed
markedly higher amounts of CD146 as compared with their
mock-transfected counterparts. This was independent of
the origin of the transfected cells, since both epithelial and
melanoma cells overexpressing Bcl-2 showed upregulated
expression of CD146 in vitro. In vivo, however, a clear-cut
correlation of CD146 expression with the expression levels
of Bcl-2 is harder to pin down: on the one hand, many me-
lanoma cells show marked upregulation of Bcl-2 and other
anti-apoptotic proteins in vivo (Um et al, 2004), an obser-
vation that is consistent with our results as well as the pre-
viously described expression of CD146 in melanomas
(Lehmann et al, 1987, 1989; Shih et al, 1994a, b). On the
other, previous studies reporting Bcl-2 expression in epi-
thelial skin tumors are less consistent inasmuch as there is
an upregulation of Bcl-2 expression in BCC, whereas most
SCC appear to downregulate Bcl-2 expression in several
studies (Morales-Ducret et al, 1995; Wikonkal et al, 1997;
Delehedde et al, 1999; Ramdial et al, 2000; Staibano et al,
2001). In psoriasis and other inflammatory skin diseases,
expression of Bcl-2 was shown to be low (Kocak et al,
2003). At least under culture conditions, as demonstrated in
our study, however, the expression of CD146 appeared to
be regulated along with the expression levels of Bcl-2, and,
possibly, susceptibility of cell lines to undergo apoptosis
in vitro. A possible functional association remains to be
elucidated and may be indirect.
Figure 5
Gp130 is identified as CD146 (MUC18, Mel-CAM, S-Endo1). In a, serial cryostat-cut sections of normal trunk skin (the two left panels; asterisks
identify a hair follicle) and a squamous cell carcinoma (the two right panels) were stained with the BT14 monoclonal antibody (mAb) or the CD146-
directed P1H12 mAb to demonstrate the similar patterns of reactivity. To prove formally that the BT14 and L101 mAb recognize CD146, sequential
immunoprecipitation (IP) and western blot (WB) experiments were performed (b). Cell lysates of the MeWo melanoma line were precleared by lectin-
based affinity chromatography, and the bound fraction containing the mannose residue-bearing glycoproteins was immunoprecipitated using the
first antibody as indicated at the bottom of the panels. The proteins were then separated by sodium dodecyl sulfate polyacrylamide gel elect-
rophoresis, and the blotted antigens were detected by the respective second antibody as indicated at the top of the panels. It is shown that each of
the monoclonal antibodies (mAb) used recognizes the antigen that has previously been precipitated by the respective other mAb. The commercially
available P1H12 mAb shows weaker reactivity in western blot as compared with the BT14 and L101 mAb. The first lanes in each panel depict
immunoblots (without previous immunoprecipitation) from crude cell lysates to demonstrate the correct size of the antigens detected. The arrow
identifies the immunoglobulin bands of the mAb used for precipitation in the first step.
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Overall, CD146 may play a dual role in skin and skin
diseases. The expression of the protein in cutaneous tumor
cells of various origin implies a role in tumor spreading and
metastasis formation as proposed earlier (Johnson et al,
1989, 1997). In addition, the expression in the suprabasal
layers of inflamed skin or in normal-appearing epidermis in
the vicinity of tumors suggests an additional, possibly dif-
ferentiation-related function.
Material and Methods
Cells and culture conditions
Normal cells Primary cultures of normal human keratinocytes
(nKC) were established from surgical specimens of human foreskin
and cultured in serum-free keratinocyte growth medium (Invitro-
gen, Karlsruhe, Germany). Human dermal microvascular end-
othelial cells (HDMEC) (a gift from C. Suschek, Institute of
Immunobiology, University of Du¨sseldorf, Germany) were grown
in Endothelial Cell Growth Medium (Invitrogen). Peripheral blood
mononuclear cells were separated from heparinized whole blood
of healthy volunteers by density gradient centrifugation using a
ficoll gradient (Pharmacia, Freiburg, Germany). After removal of
monocytes by adherence to nylon wool, the cells were plated in
RPMI medium supplemented with 10% FCS, 2 mM L-glutamine,
100 U per mL penicillin, 100 U per mL streptomycine, 5 U per mL
IL-2, and 1:3000 (w/v) PHA (phytohemagglutinin, all from Invitro-
gen). After the first day of culture, PHA was omitted.
Transformed cells SCL-1, a cell line established from a human fa-
cial squamous cell carcinoma, the spontaneously immortalized
human keratinocyte cell line HaCaT (Boukamp et al, 1988) (both
lines kindly provided by N. E. Fusenig, German Cancer Research
Center, Heidelberg, Germany), the SV40-transformed human ker-
atinocyte cell lines 425 and 130, the human colon carcinoma cell
line SK-CO-2, and the mammary carcinoma cell line HTB-26 (both
from ATCC, Manassas, Virginia) were cultured in RPMI 1640 sup-
plemented with 10% FCS, 2 mM L-glutamine, 100 U per mL pen-
icillin, 100 U per mL streptomycin, and 1% non-essential amino
acids (all from Invitrogen). The melanoma cell lines A375 (Giard
et al, 1973), Mel-HO (Holzmann et al, 1988), Mel-2A (Bruggen et al,
1981), MeWo (Bean et al, 1975), and SK-Mel-23 (ATCC) were
grown in Dulbecco’s modified Eagle’s medium (DMEM) containing
high glucose (4500 mg per L) supplemented with 10% FCS, 100 U
per mL penicillin, and 100 mg per mL streptomycin.
HaCaT, A375, and Mel-HO transfectant cell lines showing sta-
ble overexpression of functional murine Bcl-2 using the pIRES/
mbcl-2 expression construct (Mu¨ller-Wieprecht et al, 2000) were
kindly provided by C. Geilen and J. Eberle (University Medical
Center Benjamin Franklin, Berlin, Germany). Selection with 0.6 mg
per mL geneticin (G418, Invitrogen) was performed, and stable
expression of murine Bcl-2 was routinely confirmed by western
blot analysis.
To induce terminal differentiation in cultured normal human
keratinocytes and the SV40-transformed keratinocyte line 130, the
serum-free keratinocyte growth medium (containingo0.1 mM
Ca2þ ) was supplemented with 1 mM CaCl2 for 3 d. To assess
the regulation of antigen expression, cells were cultured under
conditions of serum starvation (4 d in RPMI 1640 with supplements
as above, but only 0.5% FCS), in the presence of high serum
concentrations (20% FCS for 3 d), in the presence of 8 mg per mL
mitomycin C for 24 h, or in the presence of 1.5 mM hydroxyurea for
24 h as described (Klein et al, 1988; Scho¨n et al, 1995) prior to
metabolic labeling. In another series of experiments, subconfluent
cultures of normal keratinocytes were supplemented with IL-1a
(20 pg per mL), TNF-a (5 ng per mL), GM-CSF (2 ng per mL), IFN-g
(100 ng per mL), VEGF (20 ng per mL), or IL-8 (25 ng per mL) (all
cytokines purchased from Sigma Chemicals, Deisenhofen, Ger-
many). In addition, cocktails of IL-1a, TNF-a and GM-CSF, or IFN-g
and IL-8 were used.
Monoclonal antibodies and antibody puriﬁcation Murine
monoclonal antibodies BT14 (IgG1, a kind gift from C. E. Klein,
University of Wu¨rzburg, Germany) and L101 (IgG2a, obtained from
ATCC) were used to detect a tumor-associated glycoprotein of
Mr 130 kDa (Klein et al, 1988). It was established that both
mAb worked in immunohistochemistry, immunoprecipitation, flow
cytometry (FACS), and Western blot analyses, with BT14 showing
distinctly stronger reactivity in all of the techniques. The VF18 mAb
(murine IgG2a) directed against human B-CAM (Scho¨n et al, 2000)
and the BT15 mAb (murine IgG1) detecting a differentiation-asso-
ciated glycoprotein of Mr¼ 80 kDa on human keratinocytes (Scho¨n
et al, 1995) were used as isotype-matched positive controls. Iso-
type-matched mouse IgG served as negative controls (BD Phar-
mingen, Heidelberg, Germany). The antibodies were purified from
Hybridoma culture supernatant by affinity chromatography using a
protein G-Sepharose column (Pharmacia Biotech, Freiburg, Ger-
many). Bound mAb was eluted using 0.5 M acetic acid, neutralized
with 1/20 volume of 1 M Tris pH 8.0, and dialyzed against PBS
overnight. The concentrations of purified mAb were determined
colorimetrically (Bradford assay), and the protein G-Sepharose
columns were regenerated by elution with 1 M acetic acid, pH 2.5.
The commercially available P1H12 mAb was used to detect human
CD146 (BD Biosciences, Heidelberg, Germany).
Immunohistochemistry For immunohistochemistry, 5–7 mm
cryostat-cut sections were stained by the ABC-immunoperoxidase
method (Vector, Burlingame, California). Briefly, air-dried sections
were fixed in acetone for 10 min and incubated with buffer con-
taining 10% bovine calf serum, 10% normal goat serum, 5% nor-
mal rabbit serum, and 1% normal horse serum for 30 min. Sections
were then incubated with 10 mg per mL of the primary antibody for
1 h. According to the primary antibody used, slides were then
incubated with biotinylated secondary antibody, followed by the
avidin–peroxidase complex according to the manufacturer’s in-
structions (Vector) for 45 min. Slides were then submerged in 3-
amino-9-ethylcarbazole (AEC) substrate solution in 0.1 M acetate
buffer (pH 5.2). Color development was stopped by 10% formalin
(pH 5.2) for 10 min. Subsequently, slides were counterstained with
hematoxylin and LiCO3.
Tissue samples from the following conditions were investigated
in this study: normal skin (n¼ 5), BCC (n¼ 11), SCC (n¼ 6), com-
mon warts (verruca vulgaris, n¼ 3), melanoma (n¼ 8), cutaneous
T cell lymphoma (mycosis fungoides, n¼ 4, three of which were
of the plaque stage and one was of the tumor stage), de-
rmatofibrosarcoma protuberans (n¼ 1), psoriasis (n¼ 10), allergic
contact dermatitis (n¼ 6, three of which were of acute state
and three were of chronic state), prurigo simplex (n¼ 2), and
Sweet’s syndrome (n¼ 1). The use of human tissue samples was
approved by the Ethics committee of the University of Wu¨rzburg
(19/09/2003).
FACS Adherent cells were detached using 0.5% trypsin/0.02%
EDTA in PBS, then incubated at 41C for 45 min with 10 mg per mL of
the primary mAb, washed three times in FACS buffer (PBS con-
taining 1% bovine serum albumin and 0.002% NaN3), and incubated
with phycoerythrin-conjugated goat anti-mouse IgG for 45 min at
41C. The cells were washed again three times in FACS buffer, fixed
in 2% paraformaldehyde, and analyzed using a fluorescence-acti-
vated cell scanner (FACScan, Becton Dickinson, Heidelberg, Ger-
many) and the Cell Quest software (Becton Dickinson).
Radioimmunoprecipitation Cultured cells were metabolically
labeled with 100 mCi 3SS-methionine per mL (Amersham, Braunsch-
weig, Germany) in methionine-free medium for 4 h, and subsequen-
tly solubilized in 0.5% Igepal (Sigma) supplemented with Complete
s
protease inhibitor (Boehringer Mannheim, Mannheim, Germany).
Glycoproteins were precleared by concanavalin A affinity chroma-
tography (Pharmacia). Equal amounts of radioactivity (1.5 
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106 cpm) of the concanavalin A-bound fractions were incubated
with 1.5 mg of mAb. Subsequently, the immune complexes were
precipitated using protein-G Sepharose (CL-4B from Pharmacia).
The precipitates were processed by sodium dodecyl sulfate-polya-
crylamide gel electrophoresis on 9% gels, and fluorograms were
obtained as described previously (Scho¨n et al, 2000).
Western blot analysis Cultured cells were solubilized in 0.5%
Igepal (Sigma) supplemented with Complete protease inhibitor
(Boehringer Mannheim). A Bradford assay was performed to de-
termine the protein concentrations in the lysates. Equal amounts of
protein were separated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto a nitrocellu-
lose membrane. Proteins of interest were detected by specific mAb
followed by peroxidase-labeled goat anti-mouse IgG and a chemi-
luminescence reaction (ECL from Amersham Pharmacia, Bucking-
hamshire, UK). Signals were quantitated densitometrically (Fluor-
S MultiImager, Bio-Rad, Mu¨nchen, Germany). To demonstrate
the identity of the antigens recognized by the antibodies used,
immunoprecipitation and western blot analysis were performed
subsequently.
Glycosylation studies Glycosidase digestion was carried out us-
ing immunopurified gp130 according to a previously described
method (Scho¨n et al, 1993). Briefly, the protein G immune com-
plexes were washed twice and incubated at 371C for 12 h with
0.04 U per mL neuraminidase (Sigma), 2 U per mL N-glycanase
(glycopeptidase F from Boehringer Mannheim), or, after treatment
with neuraminidase, with 0.02 U per mL O-glycanase (endo-a-N-
acetylgalactosaminidase from Boehringer Mannheim). Glycosidase
digestion was stopped using 2% SDS, and samples were proc-
essed by SDS-PAGE as described above.
Puriﬁcation of gp130 from human placenta Given that large
amounts of protein were required for purification and sequencing,
and abundant keratin proteins might interfere with the procedure,
we first determined human placenta as the best source for isolation
of sufficient amounts of the BT14/L101 antigen. In order to purify
the protein, placental tissue was cut into pieces of approximately
5 mm, lyzed in 100 mL of 0.5% Igepal (Sigma) supplemented
with Complete protease inhibitor (Boehringer Mannheim) on ice,
and disrupted further in a Potter homogenizer. The resulting crude
tissue lysate was cleared by centrifugation, and a small sample
was subjected to Western Blot analysis to confirm the BT14/L101
content.
In the next step, the BT14 mAb at a concentration of 10 mg per
mL was covalently bound to Amino-link-agarose support according
to the manufacturer’s instructions (Pierce, Rockford, Illinois). Two mL
of the BT14-linked support was incubated batchwise with 50 mL of
cell lysate on a rotating platform for 16 h at 41C. The gel was washed
5 times with 50 mL of PBS containing 8 mM 3-{(3-cholamidopropyl)
dimethylammonio}-1-propane-sulfonate, 1% deoxycholate, 0.2%
SDS, and Complete protease inhibitor. The washed gel was then
packed in a 1-cm diameter column. Gp130 was eluted with glycine-
HCl (pH 3.0) in 0.5 mL fractions, and neutralized with 25 mL of 1 M
Tris/HCl (pH 9.0). The purity of the eluted protein was assessed by
western blot analysis using the BT14 mAb.
Eluted fractions from the BT14 affinity column were dialyzed
against 10 mM NH4 acetate buffer (pH 7.0) overnight. Thereafter,
samples were concentrated in a vacuum centrifuge (SpeedVac) to
a final volume of 20 mL, and each sample was subjected to SDS-
PAGE on a 10% gel. The gels were fixed in ethanol 30% (vol/vol),
acetic acid 10% (vol/vol), and water 60% (vol/vol) overnight,
washed four times for 30 min in 20% (vol/vol) ethanol, and then
stained in 200 nm ruthenium-batho-phenantroline sulfate (RuBPS)
for at least 5 h. Protein bands were visualized using a fluorescence
imager (Molecular Imager FX, BioRad) at 488 nm for excitation and
a 520 nm long-pass filter for emission.
Tryptic digestion and mass spectrometry (peptide-mass-ﬁn-
gerprinting) Protein bands were excised from the gels after visu-
alizing by RuBPS fluorescence stain. In-gel digestion was performed
as described (Shevchenko et al, 1996) with minor modifications.
Briefly, gel pieces were washed by repeated addition and removal of
0.1 M NH4HCO3 and acetonitrile, respectively. Subsequently, the gel
particles were dried in a vacuum centrifuge, rehydrated with diges-
tion buffer containing 50 mM NH4HCO3 and 12.5 ng per mL trypsin
(sequencing grade, Boehringer Mannheim), and incubated at 371C
overnight. The peptides were extracted from the gel by repeated
addition of a sufficient volume of 25 mM NH4HCO3 and acetonitrile,
respectively. The extraction was forced by sonification. All extracts
were pooled and dried in a vacuum centrifuge.
For mass spectrometric peptide mapping, the peptides were
redissolved in 5 mL of 0.1% trifluoroacetic acid (TFA) and purified
on a 200 nL reversed-phase (C18)-nanocolumn. Peptides were elut-
ed in 5 mL of 70% (v/v) acetonitrile and, subsequently, co-crystal-
lized with a-cyano-4-hydroxycinnamic acid (20 mg per mL) in 70%
acetonitrile on a SCOUT 384-MALDI-Target. Mass spectrometry
was performed on an MALDI-TOF-MS (Reflex III, Bruker Daltonics,
Leipzig, Germany) in reflector mode with external calibration. An-
notation of the tryptic fragments was performed using the BioTools
2.0 software (Bruker Daltonics). For database search, the Mascot-
Software (Matrix Science, Boston, Massachusetts) was used.
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